Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery. Administering ...
Neoadjuvant immunotherapy in high-risk patients with hepatocellular carcinoma (HCC) led to similar recurrence-free survival (RFS) and margin-negative resection rates compared with patients undergoing ...
Outcomes for advanced hepatocellular carcinoma with pulmonary metastasis: Surgical vs. immunotherapy
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at an advanced stage due to the absence of symptoms. A key characteristic of ...
D.C.-based Current Surgical this week announced a $3.2 million seed. The round, which brings the firm’s total raise up to $4 million, was led by True Ventures and features 1517 Fund and SciFounders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback